Henry Schein Inc. has appointed three new members to its Executive Management Committee (EMC): Steve Boggan and Bianka Wilson, co-CEOs of the firm’s Global Oral Reconstruction Group (GORG); and Tom Popeck, CEO of the Healthcare Specialties Group (HSG).
 
GORG includes Henry Schein’s portfolio of premium value and value implant lines and a full range of biomaterial products. HSG includes a range of company-owned manufacturing brands in the high-growth endodontic, orthodontic, and orthopedic markets.
 
“We are delighted to welcome three strong and proven leaders to the Henry Schein Executive Management Committee,” Henry Schein Chairman/CEO Stanley Bergman said. “Steve, Bianka, and Tom have each demonstrated vision and commitment in inspiring and leading our teams to excellence in a quickly changing global healthcare marketplace. Our senior leadership team will benefit greatly from the added perspectives of these professionals.”
 
Boggan joined Henry Schein in 2013 with the company’s acquisition of BioHorizons. He began working for BioHorizons as a startup in 1995 and led the firm as president and CEO since 1999. As a GORG co-CEO, Boggan will lead commercial operations in North and South America and the Middle East as well as global marketing.
 
Wilson began working for Henry Schein in 2018 after a successful 25-year career in finance and consulting. Prior to Henry Schein, she was group CFO of Ascom Holding AG, a Swiss public company in the medical communication technology sector and, prior to that, as Advisory and Global Account lead partner at KPMG. Wilson had been serving as chief financial officer of GORG and, as co-CEO, she will lead strategy, finance, and human resources as well as the group’s business in Europe and Asia Pacific.
 
Popeck joined Henry Schein in 2019 with more than 20 years of sales leadership and general management experience, including extensive experience in the medical device sector. Prior to Henry Schein, he spent more than two decades leading businesses in orthopedics and industrial manufacturing, including spending 11 years at Stryker Corp., where he held various leadership roles, including leading Stryker’s Foot & Ankle business unit as vice president and general manager. In 2023, he was promoted to president of Henry Schein’s Healthcare Specialties Group.

The GORG and HSG businesses are central to advancing the Company’s BOLD+1 strategic plan, in particular the building of higher-growth and higher-margin specialty products and services offerings that complement our distribution, software, and value-added businesses. Together, the company is leveraging these businesses to broaden and deepen relationships with customers.
 
Henry Schein is a solutions company for healthcare professionals powered by a network of people and technology. With more than 25,000 Team Schein members worldwide, the company’s advisors provides over 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. The company’s business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. A Fortune 500 company and member of the S&P 500 index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. Its sales reached $12.3 billion in 2023, and the firm has grown approximately 11.5% annually since going public in 1995.